Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
(2015). High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation. mAbs: Vol. 7, No. 1, pp. 96-109. Via Krishan Maggon 
|
Scoop.it!
This review summarises the characteristics of rituximab and other anti-CD20 monoclonal antibodys for NHL treatment. Via Krishan Maggon
Krishan Maggon 's curator insight,
January 6, 2015 1:34 AM
Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment
*Letizia Polito, Massimo Bortolotti, Stefania Maiello, Maria Giulia Battelli, Andrea Bolognesi Department of Experimental, Diagnostic, and Specialty Medicine – DIMES, Alma Mater Studiorum – University of Bologna, Bologna, Italy Disclosure: No potential conflict of interest. |
mAbsVolume 7, Issue 1, 2015 High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation View full textDownload full textSupplementalOpen accessDOI:10.4161/19420862.2014.985522Claudia T Mendlerab, Lars Friedricha, Iina Laitinenb, Martin Schlapschya, Markus Schwaigerb, Hans-Jürgen Westerc & Arne Skerraad*
pages 96-109
Publishing models and article dates explainedReceived: 24 Aug 2014Accepted: 28 Oct 2014Accepted author version posted online: 21 Nov 2014
Published online: 14 Jan 2015Article Views: 59 Alert me© 2015 The Author(s). Published with license by Taylor & Francis Group, LLC
#m5iteumh #miscoopit